PMID- 28273369
OWN - NLM
STAT- MEDLINE
DCOM- 20180307
LR  - 20180307
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 86
IP  - 6
DP  - 2017 Jun
TI  - Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in 
      female patients with multiple endocrine neoplasia syndrome type 1?
PG  - 791-797
LID - 10.1111/cen.13324 [doi]
AB  - OBJECTIVE: Pancreatic neuroendocrine tumours (PNETs) are the most common cause of 
      death in patients with multiple endocrine neoplasia type 1 (MEN1). Women have 
      been shown to have improved survival, which may suggest a possible protective 
      effect of female sex hormones. The aim of this study was to evaluate the 
      relationship between estrogen exposure and PNET tumourigenesis, tumour growth and 
      survival in female MEN1 patients with these tumours. DESIGN: We performed a 
      retrospective chart review of the existing MEN1 database in our institution. 
      Detailed information about female patients' menstrual and reproductive history, 
      and PNET clinicopathologic characteristics was collected. Questionnaires 
      regarding estrogen exposure were used to collect information that was missing in 
      the database. PATIENTS: Of 293 confirmed MEN1 cases, 141 women met the inclusion 
      criteria. MEASUREMENTS: We used measures of cumulative estrogen exposure time 
      (CEET), parity, live birth pregnancies and bilateral oophorectomy to estimate 
      estrogen exposure. RESULTS: There was no significant association between CEET and 
      time to PNET diagnosis (hazard ratio = 0.966, P = 0.380). For the correlation 
      between estrogen exposure and PNET type, size, numbers, distant metastasis, lymph 
      node metastasis, lymphovascular invasion, AJCC (American Joint Committee on 
      Cancer) stage and overall survival, only CEET was significantly correlated with 
      PNET size (P = 0.043). CONCLUSIONS: In female patients with MEN1, estrogen 
      exposure may inhibit PNET growth. A demonstrable protective effect against PNET 
      tumourigenesis, tumour growth and survival of patients with these tumours may 
      require a larger cohort.
CI  - (c) 2017 John Wiley & Sons Ltd.
FAU - Qiu, Wei
AU  - Qiu W
AUID- ORCID: 0000-0003-1562-9197
AD  - Department of Hepatobiliary Pancreatic Surgery, The First Hospital of Jilin 
      University, Changchun, Jilin, China.
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Christakis, Ioannis
AU  - Christakis I
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Stewart, Ashley A
AU  - Stewart AA
AD  - Department of Surgery, Levine Cancer Institute, Charlotte, NC, USA.
FAU - Vodopivec, Danica M
AU  - Vodopivec DM
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Silva-Figueroa, Angelica
AU  - Silva-Figueroa A
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Chen, Huiqin
AU  - Chen H
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Woodard, Terri L
AU  - Woodard TL
AD  - Department of Gynecologic Oncology and Reproductive Medicine, The University of 
      Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Halperin, Daniel M
AU  - Halperin DM
AD  - Departments of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Lee, Jeffrey E
AU  - Lee JE
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Yao, James C
AU  - Yao JC
AD  - Departments of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Perrier, Nancy D
AU  - Perrier ND
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
LA  - eng
PT  - Journal Article
DEP - 20170406
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Estrogens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Estrogens/*physiology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/*drug therapy
MH  - Neuroendocrine Tumors/*drug therapy/mortality/pathology
MH  - Pancreatic Neoplasms/*drug therapy/mortality/pathology
MH  - *Protective Factors
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Young Adult
EDAT- 2017/03/09 06:00
MHDA- 2018/03/08 06:00
CRDT- 2017/03/09 06:00
PHST- 2016/09/06 00:00 [received]
PHST- 2016/10/31 00:00 [revised]
PHST- 2017/03/02 00:00 [revised]
PHST- 2017/03/02 00:00 [accepted]
PHST- 2017/03/09 06:00 [pubmed]
PHST- 2018/03/08 06:00 [medline]
PHST- 2017/03/09 06:00 [entrez]
AID - 10.1111/cen.13324 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2017 Jun;86(6):791-797. doi: 10.1111/cen.13324. Epub 2017 
      Apr 6.